COMPASS THERAPEUTICS, INC. Proceeds from Sale and Maturity of Marketable Securities
COMPASS THERAPEUTICS, INC. (CMPX) reported Proceeds from Sale and Maturity of Marketable Securities of $119.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $35.81M, a 33.57% increase year-over-year.
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $83.33M, a 128.68% increase year-over-year.
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $24.10M, a 4.49% decline year-over-year.
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $13.93M, a 59.52% decline year-over-year.
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $101.28M, a 24.97% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $134.97M, a 26.01% decline from fiscal 2023.
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $182.41M, a 272.61% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $48.95M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $119.14M 10-Q · filed 2026-08-06 | $143.24M derived: sum of 3 quarters · filed 2026-08-06 | $157.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $83.33M 10-Q · filed 2026-05-05 | $107.42M derived: sum of 2 quarters · filed 2026-05-05 | $121.35M derived: sum of 3 quarters · filed 2026-05-05 | $148.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $24.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $38.02M derived: sum of 2 quarters · filed 2026-03-05 | $64.84M derived: sum of 3 quarters · filed 2026-08-06 | $101.28M 10-K · filed 2026-03-05 |
| 2025-09-30 | $13.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $40.74M derived: sum of 2 quarters · filed 2026-08-06 | $77.18M 10-Q · filed 2025-11-05 | $102.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $26.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $63.25M 10-Q · filed 2026-08-06 | $88.48M derived: sum of 3 quarters · filed 2026-08-06 | $122.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $36.44M 10-Q · filed 2026-05-05 | $61.67M derived: sum of 2 quarters · filed 2026-05-05 | $96.08M derived: sum of 3 quarters · filed 2026-05-05 | $133.63M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $25.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $59.64M derived: sum of 2 quarters · filed 2026-03-05 | $97.19M derived: sum of 3 quarters · filed 2026-03-05 | $134.97M 10-K · filed 2026-03-05 |
| 2024-09-30 | $34.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $71.96M derived: sum of 2 quarters · filed 2025-11-05 | $109.74M 10-Q · filed 2025-11-05 | $161.15M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $37.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $75.33M 10-Q · filed 2025-08-11 | $126.74M derived: sum of 3 quarters · filed 2025-08-11 | $161.17M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $37.78M 10-Q · filed 2025-05-08 | $89.18M derived: sum of 2 quarters · filed 2025-05-08 | $123.61M derived: sum of 3 quarters · filed 2025-05-08 | $161.00M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $51.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $85.84M derived: sum of 2 quarters · filed 2025-02-27 | $123.22M derived: sum of 3 quarters · filed 2025-02-27 | $182.41M 10-K · filed 2025-02-27 |
| 2023-09-30 | $34.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $71.82M derived: sum of 2 quarters · filed 2024-11-12 | $131.01M 10-Q · filed 2024-11-12 | $167.21M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $37.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $96.58M 10-Q · filed 2024-08-12 | $132.77M derived: sum of 3 quarters · filed 2024-08-12 | $145.53M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $59.19M 10-Q · filed 2024-05-13 | $95.38M derived: sum of 2 quarters · filed 2024-05-13 | $108.14M derived: sum of 3 quarters · filed 2024-05-13 | $108.14M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $36.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $48.95M derived: sum of 2 quarters · filed 2024-03-21 | $48.95M derived: sum of 3 quarters · filed 2024-03-21 | $48.95M 10-K · filed 2024-03-21 |
| 2022-09-30 | $12.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $12.76M derived: sum of 2 quarters · filed 2023-11-09 | $12.76M 10-Q · filed 2023-11-09 | $12.76M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $0.00 derived: sum of 3 quarters · filed 2023-08-03 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |